Retatrutide's Phase 3 Run Is Nearly Complete. The Numbers Are the Largest Yet
TRIUMPH-2 and TRIUMPH-3 read out in July, following TRIUMPH-1 in May. Across the programme the triple agonist has produced weight loss in a range no approved obesity drug has reached, with a filing due in early 2027.
Tuesday, August 11, 2026/3 min read
Retatrutide has been the most watched molecule in metabolic medicine for three years, largely on the strength of a Phase 2 trial that produced weight loss numbers people initially assumed were a typo. The question was always whether Phase 3 would hold up. It has.
With TRIUMPH-2 and TRIUMPH-3 reading out in July 2026, following TRIUMPH-1 in May and TRIUMPH-4 in December 2025, the programme is close to complete. Eli Lilly has said it intends to file a Biologics License Application with the FDA in the first quarter of 2027.
What retatrutide is
Semaglutide targets one receptor, GLP-1. Tirzepatide targets two, GLP-1 and GIP. Retatrutide targets three, adding glucagon.
The glucagon component is the interesting one, because glucagon is conventionally thought of as the hormone that raises blood sugar. At these doses, alongside the other two, it appears to increase energy expenditure and act on hepatic fat, which is why the class is sometimes described as combining appetite suppression with a metabolic accelerator.
We covered the mechanism in more detail when the earlier trial data first emerged.
The numbers, trial by trial
TRIUMPH-1, May 2026
2,339 participants, randomised to 4 mg, 9 mg, 12 mg or placebo. At 80 weeks, average body weight reduction was 17.6 per cent on 4 mg, 23.7 per cent on 9 mg, and 25.0 per cent on 12 mg, against 3.9 per cent on placebo.
Participants with severe obesity escalated to the maximum tolerated dose reached up to 30 per cent reduction at 104 weeks.
TRIUMPH-4, December 2025
Obesity with knee osteoarthritis. Average 28.7 per cent weight reduction at 68 weeks on 12 mg, and WOMAC pain scores reduced by up to an average of 4.5 points, around 75 per cent.
The pain result matters more than it sounds. Osteoarthritis is one of the conditions where weight loss should mechanically help, and demonstrating it in a trial rather than assuming it is the difference between a plausible benefit and a reimbursable one.
TRIUMPH-2 and TRIUMPH-3, July 2026
TRIUMPH-3 studied adults with severe obesity and established cardiovascular disease, and reported up to 22.6 per cent average weight reduction at 80 weeks. That population is the one where the clinical stakes are highest and where prescribers are most cautious.
Putting 25 per cent in context
For most of the history of obesity medicine, a drug that produced 5 per cent weight loss was considered worth approving. Semaglutide at obesity doses moved that to around 15 per cent. Tirzepatide pushed it higher again.
A quarter of body weight, sustained to 80 weeks, is in the territory previously reserved for bariatric surgery. For a person of 110 kg that is roughly 27 kg.
That is genuinely a different category of intervention, and it raises questions the field has not fully answered.
The questions the numbers do not answer
Muscle
Rapid, large weight loss takes lean mass as well as fat, and the proportion matters enormously for older patients. The trials include a 4 mg maintenance arm partly for this reason. We looked at the evidence in what GLP-1 drugs do to lean mass, and it remains the most underdiscussed issue in the class.
Tolerability
Gastrointestinal side effects are the dose-limiting factor across the whole class, and a triple agonist is not gentler. The dose escalation schedules in these trials exist because people cannot start at the top.
Stopping
Weight returns when the drug stops. That is a consistent finding across the class, discussed in the evidence on stopping, and it means a 25 per cent result is a statement about a drug you are still taking.
Cardiovascular outcomes
Weight loss is a surrogate. What eventually determines the drug's place in guidelines is whether it prevents heart attacks, strokes and deaths, and those outcome trials take years.
What happens next
A BLA in Q1 2027 implies a possible approval late 2027 or into 2028, assuming a standard review and no surprises. Additional TRIUMPH results are expected through the rest of this year.
Then comes the part that determines whether any of this reaches people: manufacturing capacity and price. The GLP-1 era has been defined as much by supply and cost as by efficacy, and the Gulf market has its own version of that problem, which we examined in access and pricing across the UAE and Saudi Arabia.
A drug that produces 25 per cent weight loss and that nobody can obtain or afford is a scientific achievement rather than a public health one. That is the next argument, and it has already started.
Published in The Outspoken Digest
Editorial desk
Outspoken Digest Health DeskMedicine, public health and the research behind the headlines, read carefully.
Newsletter
The Digest, in your inbox
One edition, sent when it is ready. No noise, and your address is never passed on.
Read Next
More Health →
